A medical condition affecting an estimated 170 million women worldwide has been officially renamed after a global consensus process involving more than 14,000 survey responses and input from 56 organizations. Polycystic ovary syndrome, or PCOS, is now called PMOS1, which stands for polyendocrine metabolic ovarian syndrome.
The name change reflects a shift in how the medical community understands the condition. The old term “polycystic ovary syndrome” was always somewhat inaccurate. The structures that appear as cysts on some ultrasounds are actually immature follicles, which are a symptom of hormonal dysfunction rather than the cause. By centering the ovaries, the old terminology obscured the condition’s true nature as a multi-system syndrome involving hormones, metabolism, and ovarian function.
This naming confusion had real consequences for diagnosis. A 2025 study found that while population-based data show PCOS prevalence of 4 to 19.6 percent, health system records capture only 0.2 to 5.2 percent. This diagnostic gap is not evenly distributed. Studies show that Black and African American patients are 69 percent more likely to have a missed diagnosis compared to non-Hispanic White patients.
What the new name covers
The new name has three components. The “polyendocrine” part means the condition involves multiple hormone systems, including reproductive hormones, androgens such as testosterone, insulin, and neuroendocrine hormones that affect mood and metabolism. The “metabolic” component recognizes that insulin resistance is a core feature for many women and carries significant downstream risks. The “ovarian” part captures irregular cycles, anovulation, and fertility challenges, which are now understood as one piece of a larger puzzle.
A 2025 study describes a bidirectional relationship between insulin resistance and PMOS symptoms such as hyperandrogenism and ovulatory dysfunction. PMOS itself also increases the risk of type 2 diabetes. Research shows PMOS has reproductive, metabolic, and psychological impacts across a person’s lifespan.
How clearer terminology could improve diagnosis
When clinicians hear PCOS, they think “polycystic ovaries” and look for ovarian cysts and menstrual irregularities. When they hear “polyendocrine metabolic ovarian syndrome,” the diagnostic lens widens. This matters because many women with PMOS do not fit the narrow classic presentation. Some have regular periods. Others present with irregular menstrual cycles but do not have visible follicles on ultrasound. However, symptoms like insulin resistance, elevated androgens, acne, hair changes, or metabolic markers point to the same underlying dysfunction.
The goal is that reframing the condition as metabolic and endocrine, rather than simply gynecological, will prompt earlier and more comprehensive screening. A woman presenting with unexplained weight gain, fatigue, and skin changes might now be evaluated for PMOS rather than having her symptoms dismissed or sent to separate specialty visits.
What this means for patients
For those already diagnosed, the name change validates that the condition is not just about the ovaries. It is a whole-body condition that requires whole-body care, including metabolic screening, cardiovascular risk assessment, and attention to mental health. For those who have suspected something was wrong but have not gotten answers, the evolving understanding of PMOS may help. Patients can ask their healthcare provider about comprehensive hormone and metabolic testing, not just an ultrasound. Understanding the differences between PMOS and other conditions such as endometriosis can also help patients advocate for themselves.
The renaming of PCOS to PMOS reflects decades of research showing this condition extends far beyond the ovaries. The new terminology may lead to earlier diagnosis, more comprehensive care, and better recognition of the metabolic and hormonal factors that shape women’s health.
